{
    "organizations": [],
    "uuid": "9bb382560fe988f50f68607cf2febeb251718687",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-a1m-pharma-proposes-rights-issue-o/brief-a1m-pharma-proposes-rights-issue-of-about-sek-83-million-idUSFWN1PV0E9",
    "ord_in_thread": 0,
    "title": "BRIEF-A1M Pharma Proposes Rights Issue Of About SEK 83 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - A1M PHARMA AB:\n* PROPOSES RIGHTS ISSUE OF ABOUT SEK 83 MILLION BEFORE ISSUE COSTS TO FINANCE CLINICAL STUDIES\n* SUBSCRIPTION PRICE IS SEK 5 PER NEW SHARE‍​ * ISSUE IS SECURED TO 75 PERCENT CORRESPONDING TO SEK 62.3 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-05T15:17:00.000+02:00",
    "crawled": "2018-02-06T23:49:37.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "a1m",
        "pharma",
        "ab",
        "proposes",
        "right",
        "issue",
        "sek",
        "million",
        "issue",
        "cost",
        "finance",
        "clinical",
        "study",
        "subscription",
        "price",
        "sek",
        "per",
        "new",
        "issue",
        "secured",
        "percent",
        "corresponding",
        "sek",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}